dzd2269
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04634344)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04932005 | Phase 1 | Jun 29, 2021 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Frontage Laboratories, Inc. |
| NCT04634344 | Phase 1 | Nov 30, 2020 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 1 | 2020 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1